Immunological issues in patients with autism spectrum disorders

Neuropsychiatric Disorders and Infection

Volumn , Issue , 2005, Pages 187-197

  Jyonouchi, Harumi ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 21344464748     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (87)

1. Gillberg C, Coleman M. Biology of the Autistic Syndromes (3rd ed). Clinics in Developmental Medicine No 153/4. London: Mac Keith Press, 2000.
2. Korvatska E, Ven de Water J, Anders TF, Gershwin ME. Genetic and immunologic considerations in autism. Neurobiol Dis 2002;9:102-25.
3. Ilan K, Xiao-Song H, Gershwin ME, Yehuda S. Immune factors in autism: a critical review. J Autism Dev Disord 2002; 32: 337-45.
4. Medzhitov R, laneway C Ir. Innate immunity. New Engl J Med 2000;343:338-44.
5. Ulevitch RJ. Molecular mechanisms of innate immunity. Immunol Res 2000; 21: 49-54.
6. Wright SD. Toll, a new piece in the puzzle of innate immunity. J Exp Med 1999; 189: 605-9.
7. Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission: comparison with the effects of stress. Adv Exp Med Biol 1999; 461: 117-27.
8. Haddad JJ, Saadé NE, Safieh-Garabendian B. Cytokines and neuro-immune endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. Neuroimmunol 2002; 133: 1-19.
9. Mullington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann NY Acad Sci 2001; 933: 201-10.
10. Flavell, RA. The molecular basis of T cell differentiation. Immunol Res 1999; 19: 159-68.
11. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 12: 933-44.
12. Rogge L. A genomic view of helper T cell subsets. Ann NY Acad Sci 2002; 974: 57-67.
13. Sewell DL, Reinke EK, Hogan LH et al. Immunoregulation of CNS autoimmunity by helminth and mycobaterial infections. Immunol Lett 2002; 82: 101-10.
14. Elias JA, Lee CG, Zheng T et al. New insights into the pathogenesis of asthma. J Clin Invest 2003; 111: 291-7.
15. Woodfolk JA, Platts-Mills TA. The immune response to intrinsic and extrinsic allergens: determinants of allergic disease. Int Arch Allergy Immunol 2002; 129: 277-85.
16. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347: 911-20.
17. + T cells in autism. J Neuroimmunol 1998; 85: 106-9.
18. Singh VK. Plasma increase of interleukin-12 and interferongamma. Pathologic significance in autism. J Neuroimmunol 1996; 66: 143-5.
19. Annacker O, Powrie F. Homeostasis of intestinal immune regulation. Microbes Infect 2002; 4: 567-74.
20. Shevack EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400.
21. Umetsu DT, Mclntire JJ, Akbari O et al. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002; 3: 715-20.
22. Loustrinen L, Pirttilà T, Collin P. Celiac disease presenting with neurological disorders. Eur Neurol 1999; 42: 132-5.
23. Erb KJ, Wholleben G. Novel vaccine protecting against the development of allergic disorders: a double-edged sword? Curr Opin Immunol 2002; 14: 633-42.
24. Wakefield AJ, Anthony A, Murch SH et al. Enterocolitis in children with developmental disorders. Am ] Gastroenterol 2000; 95:2285-95.
25. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001; 20:170-9.
26. Harbour-McMenamin D, Smith EM, Blalock JE. Bacterial lipopolysaccharide induction of leukocyte-derived corticotropin and endorphins. Infect Immun 1985; 48: 813-7.
27. Payne LC, Weignet DA, Blalock JE. Induction of pituitary sensitivity to interleukin-1: a new function for corticotropin-releasing hormone. Biochem Biophys Res Cemm 1994; 198: 480-4.
28. Minagar A, Shapshak P, Fujimura R et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002; 202: 13-23.
29. Benveniste EN. Cytokines: influence on glial cell gene expression and function. In: Neuroimmunodendocrinology 3rd ed (Blalock JE, ed). Basel: Karger, 1997: 31-75.
30. Zimmerman AW. Commentary: immunological treatments for autism. In search of reasons for promising approaches. J Autism Dev Disord 2000; 30: 481-4.
31. Bezzi P, Domercq M, Brambilla L et al. CXCR4-activated astrocyte glutamate release via TNFa: amplification by microglia triggers neurotoxicity. Nature Neurosci 2001; 4: 702-10.
32. Comi AM, Zimerman AW, Frye VH et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Chil Neurol 1999; 14: 388-94.
33. Singh VK, Warren RP, Odell JD et al. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immunol 1993; 7: 97-103.
34. Singh VK, Warren RP, Averett R, Chaziuddin M. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol 1997; 17: 88-90.
35. Krause I, He XS, Gershwin ME, Shoenfeld Y. Immune factors in autism: a critical review. ] Autism Dev Disord 2002; 32: 337-45.
36. Todd RD, Ciaranello RD. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci USA 1985; 82: 612-6.
37. Singh VK, Singh EA, Warren RP. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry 1997; 41: 753-5.
38. Hickley WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254-60.
39. Schwartz M, Cohen IR. Autoimmunity can benefit self-maintenance. Immunol Today 2000; 21: 265-8.
40. Brey RL, Sakic B, Szechtman H, Denburg JA. Animal models for nervous system disease in systemic lupus erythematosus. Ann NY Acad Sci 1997; 823: 97-106.
41. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003; 199: 275-88.
42. Sakic B, Lacosta S, Denburg JA, Szechtman H. Altered neurotransmission in brains of autoimmune mice: pharmacological and neurochemical evidence. J Neuroimmunol 2002; 129: 84-96.
43. Sakic B, Laflamme N, Crnic LS et al. Reduced corticotropinreleasing factor and enhanced vasopression gene expression in brains of mice with autoimmunity-induced behavioral dysfunction. J Neuroimmunol 1999; 96: 80-91.
44. Ballok DA, Millward JM, Sakic B. Neurodegeneration in autoimmune MRL-lpr mice as revealed by fluoro jade B staining. Brain Res 2003; 964: 200-10.
45. Sakic B, Szechtman H, Denburg JA et al. Progressive atrophy of pyramidal neuronal dendrites in autoimmune MRL-lpr mice. ] Neuroimmunol 1998; 87: 162-70.
46. Shenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliférative syndrome. J Pediatr 2000; 136: 576-7.
47. Dale RC. Autoimmunity and the basal ganglia: new insights into old diseases. Q J Med 2003; 96: 183-91.
48. Swedo SE, Leonard HL, Garvey M et al. Pediatric autoimmune neuropsychiatrie disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155:264-71.
49. Hoekstra PJ, Kallenberg CGM, Korf J, Minderaa RB. Is Tourette’s syndrome an autoimmune disease? Mol Psychiatry 2002; 7: 437-45.
50. Swedo SE. Pediatric autoimmune neuropsychiatrie disorders associated with stretptoccal infections (PANDAS). Mol Psychiatry 2002; 2: S24-5.
51. Murphy MI, Pichichero ME. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatrie disorder associated with group A streptococcal infection (PANDAS). Arch Pediatr Adoles Med 2002; 156: 356-61.
52. Garvey MA, Perimutter SJ, Allen AJ et al. A pilot study of penicillin prophylaxis for neuropsychiatrie exacerbations triggered by streptococcal infections. Sci Biol Psychiatry 1999; 45: 1564-71.
53. Husby G, van de Rijin I, Zabriskie JB et al. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976; 144: 1094-110.
54. Church AJ, Cardoso F, Dale RC et al. Anti-basal ganglia antibodies in acute and persistent Sydenham’s chorea. Neurology 2002; 50: 227-31.
55. Gibofsky A, Khanna A, Suh E, Zabriske JB. The genetics of rheumatic fever: relationship to streptococcal infection and autoimmune disease. Rheumatol 1991; 18: Sl-S5.
56. Murphy TK, Goodman WK, Fudge MW et al. B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette’s syndrome? Am J Psychiatry 1997; 154: 402-7.
57. Murphy TK, Benson N, Zaytoun A et al. Progress toward analysis of D8/17 binding to B cells in children with obsessive compulsive disorder and/or chronic tic disorder. J Neuro-immunol 2001; 120: 146-51.
58. Hollander E, DelGiudice-Asch G, Simon L et al. B lymphocyte antigen D8/17 and repetitive behaviors in autism. Am J Psychiatry 1999; 156: 317-20.
59. Eisen JL, Leonard HL, Swedo SE et al. The use of antibody D8/17 to identify B cells in adults with obsessive-compulsive disorder. Psychiatry Res 2001; 104: 221-5.
60. Gupta S, Rimland B, Shilling PD. Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. J Child Neurol 1996; 11: 501-4.
61. Frielander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003; 348: 1365-75.
62. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Dis 1996; 26: 439-52.
63. Wakefield AJ, Murch SH, Anthony A et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637-41.
64. Madsen KM, Hviid A, Vestergaard M et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl j Med 2002; 347: 1477-82.
65. Màkelà A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110: 957-63.
66. Kawashima H, Mori T, Kahiwagi Y et al. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Digest Dis Science 2000; 45: 723-9.
67. Furlano R, Anthony A, Day R et al. Colonic CD8 and 78 T-cell infiltration with epithelial damage in children with autism. J Pediatr 2001; 138: 3663-72.
68. Torrente F, Ashwood P, Day R et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 2002; 7: 375-82.
69. Horvath K, Papadimitriou JC, Rabsztyn A et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999; 135: 559-63.
70. Sandler RH, Finegold SM, Bolte ER et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Chil Neurol 2000; 15: 429-35.
71. Santelmann H, Laerum E, Roennevig J, Fagertun HE. Effectiveness of nystatin in polysymptomatic patients. A randomized, double-blind trial with nystatin versus placebo in general practice. Family Practice 2001; 18: 258-65.
72. Benlounes N, Candalh C, Matarazzo P et al. The time-course of milk antigen-induced TNF-a secretion differs according to the clinical symptoms in children with cow’s milk protein. J Allergy Clin Immunol 1999; 104: 863-9.
73. Sampson HA, Anderson JA. Summary and recommendations: classification of gastrointestinal manifestations due to immunologic reactions to foods in infants and young children. J Ped Gastroenterol Nutr 2000; 30: S87-94.
74. Sicherer SH. Food protein-induced enterocolitis syndrome: clinical perspectives. ] Ped Gastroenterol Nutr 2000; 30: S45-9.
75. Nowak-Wegrzyn A, Sampson HA, Wood RA, Sicherer SH. Food protein-induced enterocolitis syndrome caused by solid food proteins. Pediatrics 2003; 111: 829-35.
76. Dupont C, Heyman M. Food protein-induced enterocolitis syndrome: laboratory perspectives. J Ped Gastroenterol Nutr 2000; 30: S50-7.
77. D’Eufemia P, Celli M, Finocchiaro R et al. Abnormal intestinal permeability in children with autism. Acta Pediatr 1996; 85: 1076-9.
78. Beutler B. TLR4 as the mammalian endotoxin sensor. Curr Top Microbiol Immunol 2002; 270: 109-20.
79. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immunol 2003; 17: 13-9.
80. Jyonouchi H, Sun S, Le H, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorders. Neuropsychobiol 2002; 46: 76-84.
81. Vojdani A, Campbell AW, Anyanwu E et al. Antibodies to neuron-specific antigens in children with autism: possible crossreaction with encephalitogenic protein from milk, Chlamydia penumoniae and streptococcus group A. J Neuroimmunol 2002; 120: 168-77.
82. Wakefield AJ, Puleston JM, Montgomery SM et al. Review article: the concept of entero-colonic encephalopahy, autism, and opioid receptor ligands. Alim Pharmacol Ther 2002; 16: 663-74.
83. Robers TJ, Peterson PK. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 2003;24:116-21.
84. Lucarelli S, Frediani T, Zingoni AM et al. Food allergy and infantile autism. Pamminerva Med 1995; 37: 137-41.
85. Knivsberg A, Richelt K, Hoien T et al. Parents’ observations after one year of dietary intervention for children with autistic syndrome. In: Psychobiology of Autism: Current Research and Practice (Shattock P, Linfoot G, eds). Sunderland: Autism Research Unit, University of Sunderland and Autism North, 1998:13-24.
86. Whiteley P, Rogers J, Savery D et al. A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism 1999; 3: 45-65.
87. 2+ signaling in human microglia. Brain Res 1999;842:159-65.